Searched for
EISAI
Eli Lilly's Alzheimer's drug donanemab approved in India, but neurologists flag cost, access barriersA new drug for Alzheimer's, donanemab, has arrived in India. It aims to slow the disease's progression by clearing brain plaques. While off...- UK, Japan set to agree $24 billion investment, tech partnershipsBritain and Japan are set to sign deals worth over 18 billion pounds. These agreements will boost investment and technology. Tens of thousa...
- Here's a long-awaited new FDA-Approved treatment for Alzheimer's - Read moreThis could mark a new era for Alzheimer's treatment as the FDA grants full approval to a promising new drug called 'Lecanemab.' The drug is...
- New Alzheimer drug 'lecanemab' by Eisai Co and Biogen shows positive results but......, read what study saysThe ‘Eisai’ and ‘Biogen’ drug slowed cognitive decline in study participants, but many experienced brain bleeds, swelling, or other side ef...
- Roche's Alzheimer's drug fails to meet goal in long awaited trialRoche's Alzheimer's drug candidate could not be shown to markedly slow dementia progression in two drug trials, leaving rivals Biogen and E...
- At last, a drug to slow down Alzheimer'sEisai Co, a Tokyo-based pharmaceutical company with a family bent and market capitalisation of $14 billion, crossed the finish line before ...
- Dr Reddy's inks pact with Citius Pharma to sell all rights to anti-cancer agent E7777Dr Reddy's will receive $ 40 million upfront upon the closing of the transaction, followed by approval milestone payment of up to $40 milli...
- Emcure to launch generic breast cancer medicineEribulin, sold by Japanese drug maker Eisai under brand name Halaven, is used to treat HER 2 negative patients. It costs Rs 5,000 per vial.
- Japanese companies make cautious return to Indian pharma marketOther drug companies whose acquisition went southwards included Mitsui & Co, which acquired a significant stake in Arch Pharma.
- Dr Reddy's Laboratories, Japan's Eisai ink licensing pact for anticancer agentIn exchange, Eisai will receive milestone payments in line with obtaining marketing approval and the achievement of agreed upon sales targe...
- Lupin gets FDA nod for generic Aricept tabletsLupin said it has received final approval from the US drug regulator to market generic Aricept tablets used for treatment of dementia.
- Helsinn Healthcare in settlement agreement with Dr Reddy'sAccording to a statement by the drug maker, Aloxi is currently distributed by Helsinn Healthcare's marketing partner, Eisai Inc in the USA.
- Glenmark gets tentative USFDA nod to sell RufinamideGlenmark Pharmaceuticals today said it has been granted tentative approval by the US health regulator to sell Rufinamide.
- Lupin launches generic GERD drug in the US marketUsed to treat gastroesophageal reflux disease.
- Japan's Eisai to launch breast cancer drug in IndiaJapan's Eisai Pharma is slated to launch in India its novel anti-cancer drug Eribulin, sold under the brand name of Halaven.
- Dr Reddy's launches Alzheimer's disease drug in US marketDr Reddy's Laboratories today said it has launched generic Donepezil Hydrochloride tablets, used to treat Alzheimer's disease, in the US ma...
- Ranbaxy drug gets US nodRanbaxy Laboratories got the exclusive rights to market a generic version of Japanese firm Eisai's blockbuster Alzheimer's drug in the US f...
- Tokyo's Eisai to invest Rs 500 cr in Vizag SEZTokyo-based pharma major Eisai has zoomed on India to set up a new Rs 500 crore manufacturing and R&D centre.
- DRL expects verdict in Aciphex case by May 15As the patent clash between Dr Reddy's Labs (DRL) and Japanese pharma firm Eisai for the control over $1.3-billion anti-ulcer drug Aciphex ...
- Japanese drug major Eisai plans production in IndiaJapanese drug major Eisai Company, which has a marginal presence in India with just two products, will soon invest Rs 180 crore to start ma...
Load More
